Dual-mobility acetabular cups increase the stability of the hip implant in patients at high risk of dislocation, impacting patient satisfaction and reducing the incidence of costly revisions
CORK, Ireland – March 5, 2018– DePuy Synthes, the orthopaedics business of Johnson & Johnson Medical Devices Companies, plans to add a dual-mobility acetabular cup to its leading hip portfolio as a result of an agreement between DePuy Ireland Unlimited Company and SERF (Société d’Etude, de Recherche et de Fabrication). SERF is a French-based orthopaedics company that has a long and respected heritage in dual-mobility technology.
Dual-mobility acetabular cups are designed to increase the stability of the hip implant in patients with a higher risk of dislocation. They feature a standard femoral head articulating within a large polyethylene liner which articulates within a metal shell. These two points of articulation are designed to reduce the risk of dislocation which can impact patient satisfaction, and dual-mobility cups may also reduce the incidence of costly revisions.
SERF has long been an innovator in dual-mobility technology, having developed the dual-mobility concept in the 1970s. DePuy Synthes is a global leader in hips, and its deep and broad portfolio includes the CORAIL® Hip Stem, which has a 96.3% survivorship at 25 years.1 “The long-term trust that orthopaedic surgeons have placed in both companies’ products is a testament to their demonstrated performance, and we look forward to integrating SERF’s dual-mobility technology with CORAIL and several of our other hip stems,” said Aaron Villaruz, Global Platform Leader, Hips, DePuy Synthes.
Per the agreement, DePuy Synthes plans to provide the latest SERF dual-mobility acetabular cup under its own brand name to global markets beginning in the latter half of 2018 subject to regulatory approvals in the US and Europe (additional registrations in certain other geographies are planned to follow).
About the Johnson & Johnson Medical Devices Companies
The Johnson & Johnson Medical Devices Companies have been working to make surgery better for more than a century. With substantial breadth and depth in surgical and orthopaedic technologies and interventional solutions, we aspire to improve and enhance medical care for people worldwide. Together, we are working to shape the future of health through differentiated products and services.
About DePuy Synthes
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements," as defined in the Private Securities Litigation Reform Act of 1995, related to a new collaboration. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges inherent in product development, including the uncertainty of obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; challenges to patents; changes in behavior and spending patterns of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and the company’s subsequent filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither DePuy Synthes nor Johnson & Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
1Vidalain JP (2011) 25-Year ARTRO Results: A Special Vintage from the Old World. In: Vidalain JP et al; The CORAIL Hip System: A Practical Approach Based on 25 Years of Experience. Springer, pg. 94-101
©DePuy Synthes 2018. All rights reserved.